Another study by Karahan N. and colleagues (2011) also confirmed that COX-2 expression is increased in BCC and suggested that COX-2 inhibition may be effective in BCC treatment, particularly for tumors with a higher level of COX-2 or a more aggressive phenotype [35]. This evidence concerns the gene PTGS2 and skin basal cell carcinoma.